When I tell people that I have enjoyed a 30-year career writing and producing television comedies, and that one of them was the long-running hit sitcom, Cheers, I know what they are thinking. They are ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the Alliance for Clinical Trials in Oncology today announced publication of the ...
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely ...
"Our Flow Cytometry MRD for Myeloma test harnesses cutting-edge science and technology to deliver ultrasensitive insights from a noninvasive blood test, thereby improving care and value for patients ...
PALO ALTO, Calif. & ROCHESTER, Minn., February 02, 2026--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the ...
Assessing adjuvant chemotherapy benefit in younger and older molecular residual disease–positive patients with stage II/III colorectal cancer. This is an ASCO Meeting Abstract from the 2026 ASCO ...
Abstract: This paper presents PyResBugs, a curated dataset of residual bugs, i.e., defects that persist undetected during traditional testing but later surface in production—collected from major ...
Residuals are one of the most essential forms of compensation for DGA members. They ensure that when work continues to generate revenue over time, the people who made it possible share in that ongoing ...
MRD testing is underutilized in clinical practice due to uncertainty in its impact on patient management decisions. The MIDAS trial suggests omitting ASCT in multiple myeloma patients achieving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results